Marisa Fusto
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study).
Journal: Infectious diseases and therapy
Published: December 22, 2025
Determinants of non-compliance with additional booster doses of the SARS-CoV-2 vaccine in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy).
Journal: Human vaccines & immunotherapeutics
Published: November 06, 2025
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study).
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: March 11, 2025
Immune Response Against Recent Omicron Sub-Lineages in Persons with HIV Receiving a Protein-Based or mRNA XBB.1.5 SARS-CoV-2 Booster Vaccine.
Journal: International journal of molecular sciences
Published: March 07, 2025
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 29, 2024
Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition.
Journal: AIDS (London, England)
Published: July 02, 2024
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
Journal: Journal of medical virology
Published: January 04, 2024
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: March 23, 2023
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Journal: EClinicalMedicine
Published: November 29, 2022
Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation.
Journal: Clinical proteomics
Published: June 13, 2022
SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH.
Journal: Viruses
Published: June 09, 2022
Last Updated: 09/26/2026